Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA2 | P29317 | 3/20 | 0.47 |
| ▸ | CASP3 | P42574 | 2/20 | 0.45 |
| ▸ | CASP2 | P42575 | 2/20 | 0.45 |
| ▸ | CALCRL | Q16602 | 3/20 | 0.44 |
| ▸ | KDM1A | O60341 | 2/20 | 0.44 |
| ▸ | TFPI | P10646 | 5/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5065437 | 0.94 | KDM1A (0.48) | EPHA2KDM1ATFPIOPRM1OPRK1 | |
| SCHEMBL5065263 | 0.90 | KDM1A (0.47) | KDM1ATFPIOPRM1OPRK1 | |
| SCHEMBL10435105 | 0.85 | EPHA2 (0.51) | EPHA2CALCRLKDM1ATFPIOPRM1 | |
| SCHEMBL9807262 | 0.84 | EPHA2 (0.61) | EPHA2KDM1ATFPI | |
| SCHEMBL30900793 | 0.83 | CALCRL (0.47) | EPHA2CALCRLKDM1A | |
| SCHEMBL7789924 | 0.82 | OPRM1 (0.48) | EPHA2OPRM1OPRK1 | |
| SCHEMBL29628862 | 0.82 | IL23R (0.48) | EPHA2CALCRLTFPIOPRM1OPRK1 | |
| SCHEMBL9691456 | 0.82 | EPHA2 (0.61) | EPHA2CALCRLKDM1ATFPIOPRM1 | |
| SCHEMBL9551264 | 0.82 | EPHA2 (0.60) | EPHA2CALCRLKDM1ATFPIOPRM1 | |
| SCHEMBL10378610 | 0.81 | EPHA2 (0.49) | EPHA2CALCRLKDM1ATFPIOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064643-A1 | Myd88 Homodimerization Inhibitors | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-03-13 | — | — | US | disclosed |
| EP-1828246-A1 | MYD88 HOMODIMERIZATION INHIBITORS | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006067091-A1 | MYD88 HOMODIMERIZATION INHIBITORS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064643-A1 | Myd88 Homodimerization Inhibitors | MYD88, TLR4, TLR6 | EPHA2 1085/4885CASP3 2109/4885CASP2 962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.